GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Expert consensus on the diagnosis and treatment of RET gene fusion non‐small cell lung cancer in China
    Wiley ; 2023
    In:  Thoracic Cancer
    Details
    In: Thoracic Cancer, Wiley
    Abstract: The rearranged during transfection (RET) gene is one of the receptor tyrosine kinases and cell‐surface molecules responsible for transmitting signals that regulate cell growth and differentiation. In non‐small cell lung cancer (NSCLC), RET fusion is a rare driver gene alteration associated with a poor prognosis. Fortunately, two selective RET inhibitors (sRETi), namely pralsetinib and selpercatinib, have been approved for treating RET fusion NSCLC due to their remarkable efficacy and safety profiles. These inhibitors have shown the ability to overcome resistance to multikinase inhibitors (MKIs). Furthermore, ongoing clinical trials are investigating several second‐generation sRETis that are specifically designed to target solvent front mutations, which pose a challenge for first‐generation sRETis. The effective screening of patients is the first crucial step in the clinical application of RET‐targeted therapy. Currently, four methods are widely used for detecting gene rearrangements: next‐generation sequencing (NGS), reverse transcription‐polymerase chain reaction (RT‐PCR), fluorescence in situ hybridization (FISH), and immunohistochemistry (IHC). Each of these methods has its advantages and limitations. To streamline the clinical workflow and improve diagnostic and treatment strategies for RET fusion NSCLC, our expert group has reached a consensus. Our objective is to maximize the clinical benefit for patients and promote standardized approaches to RET fusion screening and therapy.
    Type of Medium: Online Resource
    ISSN: 1759-7706 , 1759-7714
    URL: Article
    DOI: 10.1111/1759-7714.15105
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2559245-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors
    Wiley ; 2023
    In:  Thoracic Cancer Vol. 14, No. 12 ( 2023-04), p. 1102-1117
    Details
    In: Thoracic Cancer, Wiley, Vol. 14, No. 12 ( 2023-04), p. 1102-1117
    Abstract: Thymic epithelial tumors (TETs) are a relatively rare type of thoracic tumor, accounting for less than 1% of all tumors. The incidence of TETs is about 3.93/10000 in China, slightly higher than that of European and American countries. For resectable TETs, complete surgical resection is recommended. Radiotherapy or chemotherapy may be used as postoperative adjuvant treatment. Treatment for advanced, unresectable TETs consist mainly of radiotherapy and chemotherapy, but there is a lack of standard first‐ and second‐line treatment regimens. Recently, targeted therapies and immune checkpoint inhibitors have shown promising outcomes in TETs. Based on the currently available clinical evidences and the opinions of the national experts, the Thymic Oncology Group of Yangtze River Delta Lung Cancer Cooperation Group (East China LUng caNcer Group, ECLUNG; Youth Committee) established this Chinese expert consensus on the clinical diagnosis and treatment of TETs, covering the epidemiology, diagnosis, treatment, prognosis and follow‐up of TETs.
    Type of Medium: Online Resource
    ISSN: 1759-7706 , 1759-7714
    URL: Issue
    URL: Article
    DOI: 10.1111/tca.v14.12
    DOI: 10.1111/1759-7714.14847
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2559245-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer
    Wiley ; 2023
    In:  Thoracic Cancer Vol. 14, No. 34 ( 2023-12), p. 3421-3429
    Details
    In: Thoracic Cancer, Wiley, Vol. 14, No. 34 ( 2023-12), p. 3421-3429
    Abstract: Immune checkpoint inhibitors (PD‐1/PD‐L1 and CTLA‐4 blockade) have revolutionized the treatment landscape in non‐small cell lung cancer (NSCLC). Secondary resistance to immunotherapy (IO), which poses a substantial challenge in clinical settings, occurs in several initial responders. Currently, new treatment approaches have been extensively evaluated in investigational studies for these patients to tackle this difficult problem; however, the lack of consistency in clinical definition, uniform criteria for enrollment in clinical trials, and interpretation of results remain significant hurdles to progress. Thus, our expert panel comprehensively synthesized data from current studies to propose a practical clinical definition of secondary resistance to immunotherapy in NSCLC in metastatic and neoadjuvant settings. In addition to patients who received IO alone (including IO‐IO combinations), we also generated a definition for patients treated with chemotherapy plus IO. This consensus aimed to provide guidance for clinical trial design and facilitate future discussions with investigators. It should be noted that additional updates in this consensus are required when new data is available.
    Type of Medium: Online Resource
    ISSN: 1759-7706 , 1759-7714
    URL: Issue
    URL: Article
    DOI: 10.1111/tca.v14.34
    DOI: 10.1111/1759-7714.15157
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2559245-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma
    Wiley ; 2023
    In:  Thoracic Cancer Vol. 14, No. 26 ( 2023-09), p. 2715-2731
    Details
    In: Thoracic Cancer, Wiley, Vol. 14, No. 26 ( 2023-09), p. 2715-2731
    Abstract: Malignant pleural mesothelioma (MPM) is a malignant tumor originating from the pleura, and its incidence has been increasing in recent years. Due to the insidious onset and strong local invasiveness of MPM, most patients are diagnosed in the late stage and early screening and treatment for high‐risk populations are crucial. The treatment of MPM mainly includes surgery, chemotherapy, and radiotherapy. Immunotherapy and electric field therapy have also been applied, leading to further improvements in patient survival. The Mesothelioma Group of the Yangtze River Delta Lung Cancer Cooperation Group (East China LUng caNcer Group, ECLUNG; Youth Committee) developed a national consensus on the clinical diagnosis and treatment of MPM based on existing clinical research evidence and the opinions of national experts. This consensus aims to promote the homogenization and standardization of MPM diagnosis and treatment in China, covering epidemiology, diagnosis, treatment, and follow‐up.
    Type of Medium: Online Resource
    ISSN: 1759-7706 , 1759-7714
    URL: Issue
    URL: Article
    DOI: 10.1111/tca.v14.26
    DOI: 10.1111/1759-7714.15022
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2559245-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Chinese expert consensus on the diagnosis and treatment of HER2 ‐altered non–small cell lung cancer
    Wiley ; 2023
    In:  Thoracic Cancer Vol. 14, No. 1 ( 2023-01), p. 91-104
    Details
    In: Thoracic Cancer, Wiley, Vol. 14, No. 1 ( 2023-01), p. 91-104
    Abstract: Human epidermal growth factor receptor 2 (HER2) possesses tyrosine kinase activity and participates in cell growth, differentiation and migration, and survival. Its alterations, mainly including mutations, amplifications, and overexpression are associated with poor prognosis and are one of the major drivers in non–small cell lung cancer (NSCLC). Several clinical trials had been investigating on the treatments of HER2‐altered NSCLC, including conventional chemotherapy, programmed death 1 (PD‐1) inhibitors, tyrosine kinase inhibitors (TKIs) and antibody‐drug conjugates (ADCs), however, the results were either disappointing or encouraging, but inconsistent. Trastuzumab deruxtecan (T‐DXd) was recently approved by the Food and Drug Administration as the first targeted agent for treating HER2 ‐mutant NSCLC. Effective screening of patients is the key to the clinical application of HER2‐targeted agents such as TKIs and ADCs. Various testing methods are nowadays available, including polymerase chain reaction (PCR), next‐generation sequencing (NGS), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), etc. Each method has its pros and cons and should be reasonably assigned to appropriate patients for diagnosis and guiding treatment decisions. To help standardize the clinical workflow, our expert group reached a consensus on the clinical management of HER2‐altered NSCLC, focusing on the diagnosis and treatment strategies.
    Type of Medium: Online Resource
    ISSN: 1759-7706 , 1759-7714
    URL: Issue
    URL: Article
    DOI: 10.1111/tca.v14.1
    DOI: 10.1111/1759-7714.14743
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2559245-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China
    Wiley ; 2022
    In:  Thoracic Cancer Vol. 13, No. 21 ( 2022-11), p. 3084-3097
    Details
    In: Thoracic Cancer, Wiley, Vol. 13, No. 21 ( 2022-11), p. 3084-3097
    Abstract: Gene fusions can drive tumor development for multiple types of cancer. Currently, many drugs targeting gene fusions are being approved for clinical application. At present, tyrosine receptor kinase (TRK) inhibitors targeting neurotrophic tyrosine receptor kinase ( NTRK ) gene fusions are among the first “tumor agnostic” drugs approved for pan‐cancer use. Representative TRK inhibitors, including larotrectinib and entrectinib, have shown high efficacy for many types of cancer. At the same time, several second‐generation drugs designed to overcome first‐generation drug resistance are undergoing clinical development. Due to the rarity of NTRK gene fusions in common cancer types and technical issues regarding the complexity of fusion patterns, effectively screening patients for TRK inhibitor treatment in routine clinical practice is challenging. Different detection methods including immunohistochemistry, fluorescence in situ hybridization, reverse transcription‐polymerase chain reaction, and (DNA and/or RNA‐based) next‐generation sequencing have pros and cons. As such, recommending suitable tests for individual patients and ensuring the quality of tests is essential. Moreover, at present, there is a lack of systematic review for the clinical efficacy and development status of first‐ and second‐generation TRK inhibitors. To resolve the above issues, our expert group has reached a consensus regarding the diagnosis and treatment of NTRK gene fusion solid tumors, aiming to standardize clinical practice with the goal of benefiting patients with NTRK gene fusions treated with TRK inhibitors.
    Type of Medium: Online Resource
    ISSN: 1759-7706 , 1759-7714
    URL: Issue
    URL: Article
    DOI: 10.1111/tca.v13.21
    DOI: 10.1111/1759-7714.14644
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2559245-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    How do belowground bedrock fissures impact soil erosion on karst hillslopes under different rainfall intensity conditions?
    Wiley ; 2023
    In:  Land Degradation & Development Vol. 34, No. 6 ( 2023-04-15), p. 1830-1841
    Details
    In: Land Degradation & Development, Wiley, Vol. 34, No. 6 ( 2023-04-15), p. 1830-1841
    Abstract: In karst regions, bedrock fissures are developed via karstification, which may cause belowground soil erosion (BSE). However, few studies have quantitatively assessed the effect of bedrock fissures on BSE because BSE measurement is difficult on karst hillslopes. The objective of this study was to investigate the differences in runoff and soil erosion at the surface and belowground on karst hillslopes with and without bedrock fissures (hereafter called HS1 and HS2, respectively) under different rainfall intensities (50, 75, and 100 mm hr −1 ). The slope gradient was 5°. In the rainfall process, surface runoff (SR), subsurface runoff (SBR), soil–rock interface flow (SRIF), and underground fissure flow (UFF) data were collected on HS1 and HS2. The results showed that the SR coefficients of HS1 and HS2 were negligible (less than 1%) under rainfall intensities of 50 and 75 mm hr −1 , and UFF (56%–57%) of HS1 and SRIF (40%–44%) of HS2 dominated the runoff pattern. Under a rainfall intensity of 100 mm hr −1 , the SR coefficient increased to approximately 30% under the two treatments, and the coefficients of UFF of HS1 and SRIF of HS2 decreased to 29% and 24%, respectively. Compared to HS2, UFF of HS1 increased by 18%–39%. The SBR coefficient was lower than 10% for all rainfall events. Because SR and SBR were low under rainfall intensities of 50 and 75 mm hr −1 , the soil loss was dominated by UFF (99%–100% of the total sediment) of HS1 and by SRIF (86%–97% of the total sediment) of HS2. Under the 100 mm hr −1 rainfall intensity, almost all sediment was lost via SR under the two treatments, and the sediment loss of HS2 was 33% higher than that of HS1. Our results indicated that bedrock fissures caused more underground rainwater leakage at the SRI and further decreased surface soil erosion on karst hillslopes.
    Type of Medium: Online Resource
    ISSN: 1085-3278 , 1099-145X
    URL: Issue
    URL: Article
    DOI: 10.1002/ldr.v34.6
    DOI: 10.1002/ldr.4572
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2021787-0
    detail.hit.zdb_id: 1319202-4
    SSG: 14
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    The value of serum albumin concentration in predicting functional outcome of status epilepticus: An observational study
    Wiley ; 2023
    In:  Epileptic Disorders Vol. 25, No. 2 ( 2023-04), p. 150-159
    Details
    In: Epileptic Disorders, Wiley, Vol. 25, No. 2 ( 2023-04), p. 150-159
    Abstract: Status epilepticus (SE) is a common neurological emergency with unsatisfying prognoses, and accurate prediction of functional outcome is beneficial in clinical decision‐making. The relationship between serum albumin concentration and outcome of SE patients has yet to be unveiled. Methods Clinical profiles of SE patients admitted to Xiangya Hospital, Central South University, from April 2017 to November 2020, were analyzed retrospectively. Outcomes of SE patients at discharge were divided into two groups based on the modified Rankin Scale (mRS): favorable outcome (mRS: 0–3) and unfavorable outcome (mRS: 4–6). Results Fifty‐one patients were enrolled. Unfavorable functional outcome at discharge was reported in 60.8% (31/51). Serum albumin concentration at admission and the Encephalitis‐NCSE‐Diazepam resistance‐Image abnormalities‐Tracheal intubation (END‐IT) score remained independent predictors for functional outcome of SE patients. A lower albumin concentration at admission and higher END‐IT score indicated a higher chance of unfavorable outcome for SE patients. The cut‐off value of serum albumin to predict unfavorable outcome was 35.2 g/L, with a sensitivity of 67.7% and specificity of 85.0%, and an area under the receiver operating characteristic curve (ROC) of .738 (95% CI: .600–.876, p  = .004). The preferable END‐IT score with optimal sensitivity (74.2%) and specificity (60%) was 2 and the area under the ROC was .742, with 95% CI of .608–.876 ( p  = .004). Significance Serum albumin concentration at admission and the END‐IT score are two independent predictive factors for short‐term outcome of SE patients, moreover, the serum albumin concentration is not inferior to the END‐IT score in indicating functional outcome at discharge.
    Type of Medium: Online Resource
    ISSN: 1294-9361 , 1950-6945
    URL: Issue
    URL: Article
    DOI: 10.1002/epd2.v25.2
    DOI: 10.1002/epd2.20001
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2118181-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Draft genome sequence of ramie, Boehmeria nivea (L.) Gaudich
    Wiley ; 2018
    In:  Molecular Ecology Resources Vol. 18, No. 3 ( 2018-05), p. 639-645
    Details
    In: Molecular Ecology Resources, Wiley, Vol. 18, No. 3 ( 2018-05), p. 639-645
    Abstract: Ramie, Boehmeria nivea (L.) Gaudich, family Urticaceae, is a plant native to eastern Asia, and one of the world's oldest fibre crops. It is also used as animal feed and for the phytoremediation of heavy metal‐contaminated farmlands. Thus, the genome sequence of ramie was determined to explore the molecular basis of its fibre quality, protein content and phytoremediation. For further understanding ramie genome, different paired‐end and mate‐pair libraries were combined to generate 134.31 Gb of raw DNA sequences using the Illumina whole‐genome shotgun sequencing approach. The highly heterozygous B. nivea genome was assembled using the Platanus Genome Assembler, which is an effective tool for the assembly of highly heterozygous genome sequences. The final length of the draft genome of this species was approximately 341.9 Mb (contig N50 = 22.62 kb, scaffold N50 = 1,126.36 kb). Based on ramie genome annotations, 30,237 protein‐coding genes were predicted, and the repetitive element content was 46.3%. The completeness of the final assembly was evaluated by benchmarking universal single‐copy orthologous genes ( BUSCO ); 90.5% of the 1,440 expected embryophytic genes were identified as complete, and 4.9% were identified as fragmented. Phylogenetic analysis based on single‐copy gene families and one‐to‐one orthologous genes placed ramie with mulberry and cannabis, within the clade of urticalean rosids. Genome information of ramie will be a valuable resource for the conservation of endangered Boehmeria species and for future studies on the biogeography and characteristic evolution of members of Urticaceae.
    Type of Medium: Online Resource
    ISSN: 1755-098X , 1755-0998
    URL: Issue
    URL: Article
    DOI: 10.1111/men.2018.18.issue-3
    DOI: 10.1111/1755-0998.12766
    Language: English
    Publisher: Wiley
    Publication Date: 2018
    detail.hit.zdb_id: 2406833-0
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    Effects of bone marrow mesenchymal stem cells transfected with Ang‐1 gene on hyperoxia‐induced optic nerve injury in neonatal mice
    Wiley ; 2018
    In:  Journal of Cellular Physiology Vol. 233, No. 11 ( 2018-11), p. 8567-8577
    Details
    In: Journal of Cellular Physiology, Wiley, Vol. 233, No. 11 ( 2018-11), p. 8567-8577
    Abstract: Optic nerve injury triggered retinal ganglion cell (RGC) death and optic nerve atrophy lead to visual loss. Bone marrow mesenchymal stem cells (BMSCs) are stromal cells, capable of proliferating and differentiating into different types of tissues. This aims of this study is to investigate the role of BMSCs transfected with angiopoietin‐1 (Ang‐1) in optic nerve injury induced by hyperoxia in a neonatal mice model. Ang‐1 overexpression vector was constructed and used to transfect BMSCs. Reverse transcription‐quantitative polymerase chain reaction was performed to detect Ang‐1 expression in BMSCs. The hyperoxia‐induced optic nerve injury model was established. The optic nerves at 6–7 mm posterior to the eyeball were extracted, and were treated with luxol fast blue staining, immunohistochemistry, immunofluorescence, and transmission electron microscopy to examine the effects of Ang‐1‐modified BMSCs on optic nerve injury induced by hyperoxia. The mice in the Ang‐1 + BMSCs and BMSCs groups showed remarkably improved myelin sheaths of nerve fibers compared to the hyperoxia saline group. The positive expression and integrated optic density of Ang‐1 in the Ang‐1 + BMSCs group were significantly higher compared to the air control, hyperoxia saline and BMSCs groups. The number and diameter of myelinated nerve fibers, the diameter of axons and the thickness of myelin sheath in the air control and Ang‐1 + BMSCs groups were higher compared to the hyperoxia saline group. Our study provides evidence supporting that Ang‐1‐modified BMSCs may have preventive and therapeutic effects on hyperoxia‐induced optic nerve injury in neonatal mice.
    Type of Medium: Online Resource
    ISSN: 0021-9541 , 1097-4652
    URL: Issue
    URL: Article
    DOI: 10.1002/jcp.v233.11
    DOI: 10.1002/jcp.26501
    Language: English
    Publisher: Wiley
    Publication Date: 2018
    detail.hit.zdb_id: 1478143-8
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...